Rayence Co. Ltd (228850) - Total Liabilities

Latest as of December 2025: ₩23.85 Billion KRW ≈ $16.16 Million USD

Based on the latest financial reports, Rayence Co. Ltd (228850) has total liabilities worth ₩23.85 Billion KRW (≈ $16.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Rayence Co. Ltd cash flow conversion to assess how effectively this company generates cash.

Rayence Co. Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Rayence Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Rayence Co. Ltd (228850) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Rayence Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Rayence Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Cj Seafood
KO:011150
Korea ₩80.91 Billion
The LEADCORP Inc
KQ:012700
Korea ₩595.00 Billion
Insung Information Co. Ltd
KQ:033230
Korea ₩114.03 Billion
eMedia Holdings Limited
JSE:EMN
South Africa ZAC1.80 Billion
Ariadne Australia Ltd
AU:ARA
Australia AU$18.79 Million
Fine Blanking & Tool Co Ltd
TWO:4535
Taiwan NT$326.44 Million
Trivago NV
NASDAQ:TRVG
USA $145.15 Million
Shanghai Phoenix Enterprise Group Co Ltd B
SHG:900916
China $1.56 Billion

Liability Composition Analysis (2015–2025)

This chart breaks down Rayence Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 228850 market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 14.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Rayence Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Rayence Co. Ltd (2015–2025)

The table below shows the annual total liabilities of Rayence Co. Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩23.85 Billion
≈ $16.16 Million
-2.84%
2024-12-31 ₩24.55 Billion
≈ $16.64 Million
-33.09%
2023-12-31 ₩36.69 Billion
≈ $24.86 Million
-1.51%
2022-12-31 ₩37.25 Billion
≈ $25.24 Million
-9.63%
2021-12-31 ₩41.22 Billion
≈ $27.94 Million
+12.78%
2020-12-31 ₩36.55 Billion
≈ $24.77 Million
-3.24%
2019-12-31 ₩37.78 Billion
≈ $25.60 Million
+96.06%
2018-12-31 ₩19.27 Billion
≈ $13.06 Million
-2.74%
2017-12-31 ₩19.81 Billion
≈ $13.42 Million
-20.56%
2016-12-31 ₩24.94 Billion
≈ $16.90 Million
-26.79%
2015-12-31 ₩34.06 Billion
≈ $23.08 Million
--

About Rayence Co. Ltd

KQ:228850 Korea Medical Devices
Market Cap
$66.01 Million
₩97.41 Billion KRW
Market Cap Rank
#20808 Global
#1266 in Korea
Share Price
₩6190.00
Change (1 day)
-0.16%
52-Week Range
₩4895.00 - ₩6930.00
All Time High
₩20930.72
About

Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more